SCHEMBL3351370

SCHEMBL3351370

CN(c1ccccc1C(N)=O)S(=O)(=O)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
TSHR P16473 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
HSD17B10 Q99714 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 2/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
POLB P06746 1/20 0.36
METAP2 P50579 1/20 0.36
PDK2 Q15119 1/20 0.35
MEN1 O00255 1/20 0.35
BCAT2 O15382 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127019 0.86 KMT2A (0.45) KMT2ATSHRALDH1A1MAPTHSD17B10
Hydrochloric Acid SCHEMBL5122954 0.84 KMT2A (0.44) KMT2ATSHRALDH1A1MAPTHSD17B10
Trifluoroacetic Acid SCHEMBL30005064 0.81 KMT2A (0.55) KMT2ATSHRALDH1A1MAPTHSD17B10
SCHEMBL28002534 0.80 KMT2A (0.66) KMT2ATSHRALDH1A1MAPTHSD17B10
Hydrochloric Acid SCHEMBL30004917 0.79 KMT2A (0.64) KMT2ATSHRALDH1A1MAPTHSD17B10
Hydrochloric Acid SCHEMBL30006002 0.79 KMT2A (0.64) KMT2ATSHRALDH1A1MAPTHSD17B10
SCHEMBL2397595 0.76 GAA (0.56) KMT2AALDH1A1MAPTGAASMN1; SMN2
SCHEMBL6417177 0.74 KMT2A (0.43) KMT2ATSHRALDH1A1MAPTHSD17B10
SCHEMBL147847 0.74 ALDH1A1 (0.69) KMT2ATSHRALDH1A1MAPTHSD17B10
SCHEMBL6467738 0.73 ALDH1A1 (0.50) KMT2ATSHRALDH1A1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US claimed
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP KMT2A 4650/4885TSHR 2085/4885ALDH1A1 2133/4885
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 KMT2A 2573/4885TSHR 4721/4885ALDH1A1 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.